PDA

View Full Version : mrk

Pages : [1] 2 3 4 5 6
  1. Merck & Co., Inc. Donates Antimalarial Candidate to Medicines for Malaria Venture for
  2. Merck Climbs On Cowen Upgrade
  3. Pharma merger wrap-up: Pfizer, Merck, Roche… who’s next?
  4. SmarTrend® News Watch: Merck, Morgan Stanley, Navistar, Charlotte Russe Upgraded
  5. Merck Climbs On Cowen Upgrade
  6. Merck Climbs On Cowen Upgrade
  7. Merck launches biotech venture capital fund
  8. Xencor Licenses Xtend™ Antibody Half-Life Prolongation Platform to Merck & Co., Inc.
  9. Merck Climbs On Cowen Upgrade
  10. The Profit Pill
  11. News > Unternehmensnachrichten > Merck & Co., Inc. Provides Update on ...
  12. Merck Provides Update on Merger Financing
  13. Merck & Co., Inc. Provides Update on Previously-Disclosed US Department of Justice In
  14. Merck Provides Update on Merger Financing
  15. Merck & Co., Inc. Provides Update on Previously-Disclosed US Department of Justice In
  16. Merck Updates On $7B In Financing For Schering Buyout >MRK
  17. Merck says it's "target" of federal Vioxx probe
  18. Merck and Medicines for Malaria Venture sign licensing agreement
  19. Merck Loses JMOL Bid In ERISA Suit Over Vioxx Errors
  20. Viruses Stopped by Merck’s Gardasil Cause Most Cervical Cancer
  21. Viruses Stopped by Merck’s Gardasil Cause Most Cervical Cancer
  22. Viruses Stopped by Merck’s Gardasil Cause Most Cervical Cancer
  23. Merck Offers Update on Merger Financing
  24. Merck Offers Update on Merger Financing
  25. Merck Loses Challenge to Company Stock Fiduciary Claims
  26. UPS helps drug companies manage supply chain
  27. Xencor Inks Licensing Pact with Merck
  28. Xencor Inks Licensing Pact...
  29. Xencor Inks Licensing Pact with Merck
  30. Heart Doctor Still Likes Odds For 'Good' Cholesterol Drugs
  31. Merck Introduces Erbitux to Korea
  32. Merck KGaA and Yissum Sign R&D Collaboration Agreement
  33. Merck KGaA and Yissum Sign R&D Collaboration Agreement
  34. Merck KGaA and Yissum Sign R&D Collaboration Agreement
  35. Merck KGaA and Yissum Sign R&D Collaboration Agreement
  36. Merck hikes investment in Irish biologics plant
  37. Heart Doctor Still Likes Odds For 'Good' Cholesterol Drugs
  38. Options Update: Wyeth and Schering-Plough volatility flat; on buyout spreads of 8%
  39. drug link to heart woes 'was known'
  40. Merck hikes investment in Irish biologics plant
  41. To drug firms, UPS a cure for logistics
  42. AstraZeneca's Crestor Doesn't Help Dialysis Patients
  43. Merck hikes investment in Irish biologics plant
  44. Merck hikes investment in Irish biologics plant
  45. Is Gardasil More Effective in Older Teens?
  46. AstraZeneca's Crestor Doesn't Help Dialysis Patients
  47. Options Update: Wyeth and Schering-Plough volatility flat; on buyout spreads of 8%
  48. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  49. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  50. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  51. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  52. Insmed Completes Sale Of Follow-on Biologics Business To Merck For $130 Mln. - Update
  53. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  54. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  55. Insmed Completes Sale Of Follow-on Biologics Business To Merck For $130 Mln. - Update
  56. Insmed Completes Sale Of Follow-on Biologics Business To Merck For $130 Mln. - Update
  57. Insmed Completes Sale Of Follow-on Biologics Business To Merck For $130 Mln. - Update
  58. Insmed Completes Sale Of Follow-on Biologics Business To Merck For $130 Mln. - Update
  59. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  60. Insmed Completes Sale Of Follow-on Biologics Business To Merck For $130 Mln. - Update
  61. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  62. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  63. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross
  64. Eli Lilly CEO Says Another Acquisition To Come
  65. Rosetta Biosoftware signs licence agreement with Stanford University for Syllego syst
  66. New Merck Programs Address Uncertainty of Insurance Coverage for HPV Vaccination
  67. SGP/Merck Merger Makes Sense
  68. New Merck Programs Address Uncertainty of Insurance Coverage for HPV Vaccination
  69. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
  70. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
  71. FDA panel happy with Onglyza cardiovascular profile
  72. BTG Hires Three Executives To Spearhead US Push
  73. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
  74. Merck & Co., Inc. - Financial and Strategic Analysis Review
  75. Merck & Co., Inc. - Financial and Strategic Analysis Review
  76. Merck to Benefit in SGP Deal
  77. Young eye researchers receive prestigious ARVO-AFER/Merck award
  78. German drug, chemical firm Merck to cut production
  79. Merck to Benefit in SGP Deal
  80. Insmed, Merck close deal
  81. PhRMA Honors Gardasil(r) Researchers With Discoverers Award
  82. Merck CEO: Drug Companies Need to Repair “Trust Deficit” With the Public. Um, Yeah.
  83. Merck CEO: Drug Companies Need to Repair “Trust Deficit” With the Public. Um, Yeah.
  84. Insmed completes sale of follow-on biologics business to Merck
  85. Zacks Analyst Blog Highlights: Merck & Co., Schering-Plough, Johnson & Johnson, Micro
  86. Biotech Poised to Disappoint (MRK, GILD, CELG)
  87. J&J: Co Doesn't Have Plans To Enter 'Biosimilars' Market
  88. J&J: Co Doesn't Have Plans To Enter 'Biosimilars' Market
  89. Schering-Plough, Merck set $41.1B merger
  90. Egis agrees with MSD to sell Januvia in Hungary
  91. Doctors signed Merck's Vioxx studies
  92. Blueprint and Merck to Present at the Project Summit and Business Analyst World
  93. Doctors signed Vioxx studies
  94. Breaking down the Merck-Schering-Plough merger
  95. New Merck Programs Address Uncertainty of Insurance Coverage for HPV Vaccination
  96. Breaking down the Merck-Schering-Plough merger
  97. New Merck Programs Address Uncertainty of Insurance Coverage for HPV Vaccination
  98. Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigati
  99. THE INFLUENCE GAME: Firms reap seeds of lobbying
  100. Cardiome Shares Jump Pre-Market On Merck Deal >CRME
  101. SmallCapReview.com: Stocks to Watch Thursday - HA, MRK, CAT, CRME
  102. SmallCapReview.com: Stocks to Watch Thursday - HA, MRK, CAT, CRME
  103. CRME: Collaboration and License Agreement w/Merck for Vernakalant
  104. Cash: The Cure for Smaller Drugmakers
  105. Cash: The Cure for Smaller Drugmakers
  106. Cash: The Cure for Smaller Drugmakers
  107. Township seeks Merck-funded upgrade
  108. Merck & Co., Inc. And Cardiome Sign License Agreement For
  109. Bristol-Myers on the Prowl for Deals – BMY, PFE, MRK, AZN
  110. A doctor alleges Merck & Co reps visited him 124 times but never talked of drug risks
  111. Merck & Co., Inc. and Santen Sign Licensing Agreement In Ophthalmology
  112. Big Pharma Blames Its Troubles on Scientists
  113. Big Pharma Blames Its Troubles on Scientists
  114. Nikkei set to rise on Wall St gain, NEC Elec eyed
  115. Nikkei set to rise on Wall St gain, NEC Elec eyed
  116. Nikkei set to rise on Wall St gain, NEC Elec eyed
  117. Drug reps given cheatsheets
  118. Merck team honored for work to develop Gardasil
  119. Briefing - asia health - april 16, 2009
  120. AARP: Brand-name drug prices, use of generics up
  121. Briefing - asia health - april 16, 2009
  122. Addex Shareholders Approve All Board Proposals at 2009 AGM
  123. News > Unternehmensnachrichten > Addex Shareholders Approve All Board Proposals ...
  124. Merck, Biogen Boost Lobbying to Defy Obama’s Drug Comparisons
  125. Addex Shareholders Approve All Board Proposals at 2009 AGM
  126. Merck, Biogen Boost Lobbying to Defy Obama’s Drug Comparisons
  127. Merck, Biogen Boost Lobbying to Defy Obama’s Drug Comparisons
  128. 1.6-MW of Solar Energy Activated at Merck Headquarters
  129. Merck, Biogen Boost Lobbying to Defy Obama’s Drug Comparisons
  130. 3rd Merck Singulair Suit Stayed For Ruling In 1st Case
  131. Analysts look for news on Merck tie-up, key drugs
  132. Experts 'a guise' to boost new drug
  133. WSJ: GlaxoSmithKline near deal to acquire Stiefel Labs for about $3 bln - Update
  134. Galapagos enters strategic alliance in inflammatory diseases with Merck & Co., Inc.
  135. Galapagos enters strategic alliance in inflammatory diseases with Merck & Co., Inc.
  136. EARNINGS OUTLOOK Merck, Schering-Plough to release earnings Tuesday
  137. EARNINGS OUTLOOK Merck, Schering-Plough to release earnings Tuesday
  138. Preclinical Data Presented on ARIAD’s Investigational mTOR Inhibitor, Deforolimus, in
  139. Solar Energy to Power Merck World HQ
  140. Actelion Ends Phase I Blood Pressure Drug Development
  141. Actelion Ends Phase I Blood Pressure Drug Development
  142. Wall Street-Trimestrali 21/4, Coca-Cola,Caterpillar,DuPont,Merck
  143. Schering-Plough 1Q Net More Than Doubled On 2008 Charges
  144. Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusi
  145. Mass. Biologic Labs will share in $60m payment
  146. Merck To License Infection Drug For Up To $225 Million
  147. Merck Q1 profit plunges - Quick Facts 1
  148. Merck sees 57 percent drop in first-quarter profit
  149. Merck sees 57 percent drop in first-quarter profit
  150. US stock futures turn lower as DuPont, Merck cut view
  151. Schering-Plough Tops Q1 EPS Estimates, Merck Merger "On Track"
  152. Merck profit drops, company cuts revenue
  153. BEFORE THE BELL-Merck down in premarket after Q1 results
  154. BEFORE THE BELL-Merck down in premarket after Q1 results
  155. * Caterpillar, Merck, DuPont, Coca-Cola report results
  156. Schering-Plough Tops Q1 EPS Estimates, Merck Merger "On Track"
  157. Schering-Plough Q1 Profit Surges, Tops Estimates - Update
  158. Firms called a truce on safety issues
  159. Markets guarded after corporate reports
  160. Merck Serono introduces Kuvan in Europe
  161. Merck Misses Q1 Estimates, Guidance Mixed
  162. Merck, PowerShares QQQ Trust: Money Flow Leaders (MRK, QQQQ)
  163. Drug Stocks Mixed; Merck Tumbles On Weak Quarterly Report
  164. Addex Shareholders Approve All Board Proposals at 2009 AGM
  165. STOCKS NEWS US-Merck results weigh on peers
  166. STOCKS NEWS US-Merck results weigh on peers
  167. Merck, PowerShares QQQ Trust: Money Flow Leaders (MRK, QQQQ)
  168. Delayed Glaxo Cancer-Vaccine Study Raises Eyebrows, Tests Merck
  169. Medarex Sharing up to $225M from Antibody Deal with Merck
  170. STOCKS NEWS US-Merck results weigh on peers
  171. Global Investment News Briefs
  172. Zacks Analyst Blog Highlights: Merck & Co., Inc., Ardea Biosciences, Inc., DuPont, BJ
  173. SP chief Hassan pleased with first-quarter performance
  174. Delayed Glaxo Sex-Virus Vaccine Study Raises Eyebrows
  175. Colorado BioScience Association Names Rick Jory Board Chair, Announces 2009 Sponsors,
  176. Glaxo Compares Sex Virus Shots, Delay Raises Eyebrows
  177. Merck delays plan to seek FDA approval for migraine drug
  178. Merck secures global rights to 2 monoclonal antibodies
  179. Mixed Picture For Health Care Sales At Schering-Plough And Merck & Co As Acquisition
  180. Drug expert queried Vioxx research
  181. Allergic reactions to Gardasil uncommon: Study
  182. Merck's First-Quarter Profit Falls 57%, an Industrial Info News Alert
  183. CIGNA and Merck Sign Performance-Based Contract
  184. Prognostic Information From Cardiopulmonary Exercise Testing in Idiopathic Pulmonary
  185. GlycoFi Figures Heavily into Drug Giant Merck’s Follow-on Biologics Plans
  186. Stock Alerts for EBAY, MRK, PRU, PX, and DHI Released by Seven Summits Research
  187. Company and People Notes: GSK Acquires Stiefel Laboratories; Roche Announces Changes
  188. Evidence and PR spin collide in Vioxx courtroom battle
  189. J&J CEO: 'Engaged In Discussion' Over Schering Remicade Pact
  190. The courtroom battle where evidence and PR spin collide
  191. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Cent
  192. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Cent
  193. Merck & Co: Medarex deal provides access to large Clostridium difficile opportunity
  194. Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral H
  195. Merck & Co Q1 Net Income Down
  196. Merck & Co Q1 Net Income Down
  197. Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral H
  198. Big Pharma's Buying Spree (PFE, WYE, MRK)
  199. Merck-Medco Dropped From Vioxx ERISA Litigation
  200. US Stocks Fall, Halting Six-Week Winning Streak as Banks Drop
  201. US Stocks Fall, Halting Six-Week Winning Streak as Banks Drop
  202. Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusi
  203. Asia Day Ahead: US Dollar Wins Heads-or-Tails Toss on Economy
  204. Research and Markets Offers Report on Merck Serono SA - Strategic Analysis Review
  205. Merck KGaA 1Q Net -76%; FY Rev Growth Seen Up To 5%
  206. Merck’s Prescription for Corporate Responsibility
  207. Cigna and Merck sign agreement for oral anti-diabetes medications
  208. NextBio Announces Licensing Agreement with Merck & Co., Inc.
  209. Merck Getting Power From The Sun Above
  210. UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine
  211. At NJSO spring gala, Merck's Clark announces WQXR gift of symphony music
  212. Executive's doubt on Vioxx heart-trouble tactic
  213. Executive's doubt on Vioxx heart-trouble tactic
  214. Pfizer's Q1 likely to be unhealthy - earnings preview
  215. Merck partners with 2 universities to develop chlamydia vaccine
  216. Pfizer's Q1 likely to be unhealthy - earnings preview
  217. Doctors feted by Merck over Vioxx
  218. Pfizer's Q1 likely to be unhealthy - earnings preview
  219. Pfizer's Q1 likely to be unhealthy - earnings preview
  220. Cigna and Merck sign on oral anti-diabetes medications
  221. Irving Kahn adds to MBIA, Merck, The New York Times, reduces IDT, KeyCorp, and Questa
  222. Pfizer's Q1 likely to be unhealthy - earnings preview
  223. Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program
  224. Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program
  225. Company and People Notes: CIGNA and Merck Agree on Drug Pricing Plan; Kathleen Sebeli
  226. Merck-Cigna Pave Path for Performance Comparison
  227. SEC Probes Schering Trades Before Merck Deal
  228. SEC Probes Schering Trades
  229. SEC Probes Schering Trades Before Merck Deal
  230. NextBio Inks Licensing Pact with Merck
  231. SEC Probing Pre-merger Schering-Plough Trades: WSJ
  232. SEC Probing Pre-merger Schering-Plough Trades: WSJ
  233. Merck & Co: Medarex deal provides access to large Clostridium difficile opportunity
  234. Merck Created Phony Peer-Review Medical Journal
  235. Merck Created Phony Peer-Review Medical Journal
  236. SurModics Sell Rating Maintained
  237. 10-q: Merck & co inc
  238. Merck begins Vioxx defence
  239. US expert to back firm on Vioxx
  240. Merck Published Bogus Journal
  241. Accelrys Leads Consortium That Receives Best Practices Award for "Biological Knowledg
  242. Why Standard Flu Vaccines Won’t Make Investors Rich
  243. Why Standard Flu Vaccines Won’t Make Investors Rich
  244. Merck says Vioxx had heart-risk 'association'
  245. Merck says Vioxx had heart-risk 'association'
  246. Vaxent Named Finalist In World Vaccine Competition
  247. Reportlinker: High Growth Forecasted for the Merck & Co. Inc: Pharmavitae Profile
  248. iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant
  249. 10-q: Idera pharmaceuticals, inc.
  250. Reportlinker: High Growth Forecasted for the Merck & Co. Inc: Pharmavitae Profile